Plain-English translation of NCT06562647 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing , a new type of cell-based therapy designed to fight ovarian cancer. The medication works by targeting a specific protein called mesothelin found on cancer cells, and it's being given alongside an immune-boosting antibody to help your body's immune system recognize and attack the cancer.
Ovarian cancer that has progressed despite prior treatments is difficult to manage, and doctors are looking for new approaches. This trial exists to see whether combining this targeted cell therapy with immune support can safely help patients whose cancer cells express the mesothelin protein.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous injections of the new cell therapy on specific days (day 1, day 3, and possibly day 5), combined with an immune-boosting antibody injection before the first treatment. The trial starts with careful safety monitoring after the first patient, and you would need to attend follow-up visits to have your blood checked, imaging scans performed, and your response to treatment evaluated over several months.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Sponsor
Cell Origin Biotech (Hangzhou) Co., Ltd.
Enrollment target
~2 participants
Started
April 2023
Primary completion
December 2026
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in February 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.